Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/154898
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAng, Hui Yingen_US
dc.contributor.authorXiong, Gordon Minruen_US
dc.contributor.authorChaw, Su Yinen_US
dc.contributor.authorPhua, Jie Liangen_US
dc.contributor.authorNg, Jaryl Chen Koonen_US
dc.contributor.authorWong, Philip En Houen_US
dc.contributor.authorVenkatraman, Subbuen_US
dc.contributor.authorChong, Tze Tecen_US
dc.contributor.authorHuang, Yingyingen_US
dc.date.accessioned2022-01-13T04:17:46Z-
dc.date.available2022-01-13T04:17:46Z-
dc.date.issued2020-
dc.identifier.citationAng, H. Y., Xiong, G. M., Chaw, S. Y., Phua, J. L., Ng, J. C. K., Wong, P. E. H., Venkatraman, S., Chong, T. T. & Huang, Y. (2020). Adventitial injection delivery of nano-encapsulated sirolimus (Nanolimus) to injury-induced porcine femoral vessels to reduce luminal restenosis. Journal of Controlled Release, 319, 15-24. https://dx.doi.org/10.1016/j.jconrel.2019.12.031en_US
dc.identifier.issn0168-3659en_US
dc.identifier.urihttps://hdl.handle.net/10356/154898-
dc.description.abstractEndovascular therapy in peripheral intervention has grown exponentially in the past decade, but the issue of high restenosis rates in lower extremity arteries still persist. While drug-coated balloons (DCB) have been the device of choice, recent controversary regarding the long-term safety of paclitaxel have raised concern over current DCBs. In our study, we proposed that the direct injection of a sirolimus nanoliposomal formulation (Nanolimus) using a infusion catheter can attenuate inflammation response in injured vessels. In vitro characterization showed retention of the nanoliposomes size and detectable drug amount up to 336 days in storage. For in vivo study, four female, mixed breed swines were subjected to balloon injury of the femoral arteries before treatment with either injection of saline (n = 4) or Nanolimus (n = 12) using the Bullfrog catheter. Pharmacokinetic analysis demonstrated sustained sirolimus release in the arteries and undetectable systemic drug level at 28 days. Arteries treated with Nanolimus showed significant reduction in neointima area (0.2 ± 0.3 mm2 vs 2.0 ± 1.2 mm2, p < 0.01) and luminal stenosis (14.2 ± 7.2% vs. 67.7 ± 24.8%, p < 0.01) compared to controls. In summary, adventitial delivery of sirolimus using an infusion catheter is a feasible and safe method to reduce vascular restenosis.en_US
dc.description.sponsorshipNanyang Technological Universityen_US
dc.description.sponsorshipSingapore-MIT Alliance for Research and Technology (SMART)en_US
dc.language.isoenen_US
dc.relationNGF-2018-05-023en_US
dc.relationING149090-BIOen_US
dc.relation.ispartofJournal of Controlled Releaseen_US
dc.rights© 2019 Elsevier B.V. All rights reserved.en_US
dc.subjectEngineering::Materialsen_US
dc.titleAdventitial injection delivery of nano-encapsulated sirolimus (Nanolimus) to injury-induced porcine femoral vessels to reduce luminal restenosisen_US
dc.typeJournal Articleen
dc.contributor.schoolSchool of Materials Science and Engineeringen_US
dc.identifier.doi10.1016/j.jconrel.2019.12.031-
dc.identifier.pmid31863795-
dc.identifier.scopus2-s2.0-85076836997-
dc.identifier.volume319en_US
dc.identifier.spage15en_US
dc.identifier.epage24en_US
dc.subject.keywordsPeripheral Artery Diseaseen_US
dc.subject.keywordsVascular Restenosisen_US
dc.description.acknowledgementThis work has been funded by the SMART Innovation Grant (ING149090-BIO) and the Nanyang Technological University Gap Fund (NGF-2018-05-023)en_US
item.grantfulltextnone-
item.fulltextNo Fulltext-
Appears in Collections:MSE Journal Articles

SCOPUSTM   
Citations 20

8
Updated on Jul 5, 2022

Web of ScienceTM
Citations 20

7
Updated on Jul 7, 2022

Page view(s)

54
Updated on Sep 29, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.